Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

ROCKVILLE, Md., May 8 /PRNewswire-FirstCall/ - Novavax Inc. (Nasdaq: NVAX) today announced financial results for the first quarter of 2009. Novavax reported a net loss of $8.3 million, or $0.12 per share, for the first quarter of 2009 compared to a net loss of $7.8 million, or $0.13 per share, for the first quarter of 2008. The Company spent a total of $7.4 million in the first quarter of 2009 and ended the quarter with $25.6 million in cash and short-term investments. During the quarter, the Company made significant progress in developing its vaccine pipeline, improved its balance sheet by raising capital and retiring a majority of its convertible debt, and completed a transaction with Cadila Pharmaceutical Limited to create a Joint Venture Company in India.

Specifically accomplishments since the 2008 year end financial results include the following:

  • Commenced development of a VLP vaccine candidate against the novel influenza A (H1N1) virus that has recently emerged in the United States and Mexico.
  • Publication of results in the Journal of Virology from preclinical studies conducted under a collaborative research and development agreement (CRADA) between the Centers for Disease Control and Prevention (CDC) and Novavax showing that an investigational H1N1 VLP vaccine based on the 1918 Spanish influenza strain protected against both the Spanish flu and a highly pathogenic H5N1 avian influenza strain.
  • Announced the initiation of enrollment in the second Phase II study of its trivalent seasonal influenza VLP vaccine candidate. This clinical trial is designed to evaluate the safety and immunogenicity of a broader range of vaccine doses and to provide data to help select doses for future studies in older adults and a Phase III efficacy study. The Company plans to report top-line immunogenicity and safety results from this study by the fourth quarte
    '/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2010)... "Company") (Nasdaq: CMED ), a leading China -based advanced in-vitro,diagnostic ("IVD") company, today announced ... Investor Conference Date ... Rodman & Renshaw Annual March 7-9, 2010 ... ... Credit Suisse Asian ...
(Date:2/8/2010)... schedule ,, TSX Exchange Symbol: RVX ,, CALGARY, ... the "Company") (TSX:RVX) announced today the completion of patient ... lead drug RVX-208. "The completion of enrollment for our ... of our original schedule, is a very exciting achievement ... Clinic. At this rate we could be seeing the ...
(Date:2/8/2010)... communications agency, announced today that it has been selected by ... in Asia Pacific, to develop and execute its corporate communications ... ... Salem, MA (Vocus) February 8, 2010 -- LaVoie Group ... it has been selected by Invida Group , the ...
(Date:2/8/2010)... to announce that it has hired Lisa Wichman and Sahar Meyer to ... as an Account Manager and will focus on key healthcare markets in ... of that group Omaha, NE. , ... Foothill Ranch, CA (Vocus) February ... announce the hiring of a new Account Manager and Manager of Analytics. ...
Breaking Biology Technology:China Medical Technologies to Participate Investor Conferences in March 2010 2Resverlogix Completes Patient Recruitment for ASSERT Trial 2Resverlogix Completes Patient Recruitment for ASSERT Trial 3Resverlogix Completes Patient Recruitment for ASSERT Trial 4Invida Selects LaVoie Group as Public Relations Agency of Record 2Invida Selects LaVoie Group as Public Relations Agency of Record 3Healthcare Data Solutions Announces Expansion of its Healthcare Customer Solutions Team With Two Key Additions 2Healthcare Data Solutions Announces Expansion of its Healthcare Customer Solutions Team With Two Key Additions 3
... Murray Grossan, MD (creator of the Hydro-Pulse sinus irrigation ... anti-fungals and anti-inflammatories directly into the sinus cavities using ... helpful for his patients who experience symptoms of sinus ... ...
... 30 Nektar,Therapeutics (Nasdaq: NKTR ) will announce ... 2008 on Wednesday, August 6, 2008, after the,close of ... will host a conference call to review the results,beginning ... (PT)., The press release and a live audio-only ...
... SAN DIEGO, July 30 Anadys Pharmaceuticals,Inc. (Nasdaq: ... care by developing novel medicines in the areas of,hepatitis ... for the second quarter ended June 30, 2008., ... productive time at,Anadys," said Steve Worland, Ph.D., President and ...
Other Biology Technology:Prominent Physician Achieves Success Using Topical Sinus Medications via Pulsitile Irrigation 2Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets 2Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights 2Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights 3Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights 4Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights 5Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights 6Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights 7
(Date:2/9/2010)... the Hood Center for Children and Families at Dartmouth ... on the significant potential negative impact that food product ... , The study, which appears in the current edition ... of the "brand placements" for food, beverage, and food ... for energy-dense, nutrient-poor foods or product lines. In addition, ...
(Date:2/9/2010)... The Scripps Research Institute have discovered a potential new ... for sheep and cattle infected with liver fluke. The ... in combating river blindness, a tropical disease that is ... humans. , The study is scheduled for publication ... Proceedings of the National Academy of Sciences ...
(Date:2/9/2010)... they say is a strong candidate for involvement in ... the natural flux in hormones during the menstrual cycle. ... of the National Academy of Sciences , Rockefeller University ... human variant of the gene increases anxiety, dampens curiosity ... impairing memory. If applied in the clinic, the work ...
Breaking Biology News(10 mins):New study examines the impact on children of food product placements in the movies 2New study examines the impact on children of food product placements in the movies 3Scripps research team reveals how an old drug could have a new use for treating river blindness 2Scripps research team reveals how an old drug could have a new use for treating river blindness 3Scripps research team reveals how an old drug could have a new use for treating river blindness 4Research identifies gene with likely role in premenstrual disorder 2Research identifies gene with likely role in premenstrual disorder 3GAA Calls on President Obama to Make Good on His Nobel Peace Prize Speech 63059 1GAA Calls on President Obama to Make Good on His Nobel Peace Prize Speech 63059 2West Coast Banks Salem Battle Creek Branch is Collecting Teddy Bears for Sick Children at the Salem Hospital 63054 1Successful Stem Cell Therapy for Treatment of Eye Disease 15140 1Successful Stem Cell Therapy for Treatment of Eye Disease 15140 2Successful Stem Cell Therapy for Treatment of Eye Disease 15140 3Successful Stem Cell Therapy for Treatment of Eye Disease 15140 4
... process of how the body's nervous system relays information may ... fires a packet of neurotransmitter across a synapse to a ... University of Illinois at Chicago biology professor Simon Alford report ... of the National Academy of Sciences. , "Until recently, the ...
... cured the metabolic symptoms of 11 patients with a ... Urine Disease (MSUD), according to a study by researchers ... Special Children. , All patients from the study (ranging ... normal liver function, according to the researchers. Amino acid ...
... percent of deaths from SIDS (sudden infant death syndrome) in ... and half of those deaths result from a common genetic ... heart rhythm during times of environmental stress, a research team ... 2006 issue of the Journal of Clinical Investigation. , ...
Other Biology News:Protein receptor cools passion of 'kiss and run' nerve cells 2Pennsylvania researchers find liver transplants provide metabolic cure for rare genetic disease 2Gene variation increases SIDS risk in African Americans 2Gene variation increases SIDS risk in African Americans 3
... LC Sciences provides a genome-wide microRNA (miRNA) ... proprietary probe design, which enable highly sensitive ... We have standard arrays for mature miRNA ... version of the Sanger miRBase database (Release ...
... studies, vaccine development, and biosensor development ... Paraflo microfluidic on-chip synthesis platform. These ... our comprehensive Epitope Peptide Microarray Service. ... Probe content is completely customer specified. ...
... peptide microarrays designed for quantitative assays ... and built on the flexible and ... of customer specified sequences can be ... provide assistance with custom sequence design. ...
... first time, you can identify and characterize ... without interferences. The Agilent Multiple Affinity Removal ... high-abundant proteins from human serum, plasma, CSF ... device. With this revolutionary system, you can: ...
Biology Products: